Recent News

• 04.22.2025 - IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
• 03.31.2025 - IceCure to Exhibit and Join the Hands-on Cryoablation Sessions at the European Conference on Interventional Oncology (ECIO) 2025
• 03.27.2025 - IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
• 03.24.2025 - IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
• 03.21.2025 - IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
• 03.20.2025 - IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
• 03.18.2025 - IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
• 03.17.2025 - IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
• 03.13.2025 - IceCure to Exhibit at 2025 American Society of Breast Surgeons (ASBrS) Annual Meeting

Recent Filings

• 04.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.27.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.27.2025 - EX-99.1 EX-99.1
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2025 - EX-99.1 EX-99.1
• 03.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.17.2025 - EX-99.1 EX-99.1